Rebecca A. Shatsky, MD, a medical oncologist, provides clinical insights on biomarker testing paradigms for patients with ER+/HER2- metastatic breast cancer.
EP. 1: Overview of ER+/HER2- Metastatic Breast Cancer
Rebecca A. Shatsky, MD, provides an overview of ER+/HER2- metastatic breast cancer and discusses its incidence and prevalence.
EP. 2: Clinical Biomarkers in Metastatic Breast Cancer
A medical oncologist discusses molecular biomarkers identified in patients with metastatic breast cancer and compares ESR1 with other genetic mutations.
EP. 3: Sampling Methods for Patients with Metastatic Breast Cancer
An expert on breast cancer provides clinical insights on liquid and tissue biopsies for patients with metastatic disease.
EP. 4: Guideline Recommendations for Biomarker Testing in Breast Cancer
Rebecca A. Shatsky, MD, reviews biomarker testing guideline recommendations for patients with breast cancer and discusses testing practices upon progression.
EP. 5: EMERALD Trial: Elacestrant for ER+/HER2- Metastatic Breast Cancer
A review of results from the EMERALD trial investigating elacestrant in patients with ESR1-mutated metastatic breast cancer.
EP. 6: Evolving Practice Standards for ER+/HER2- Metastatic Breast Cancer
A medical oncologist discusses challenges with conducting molecular testing and reviews clinical trials focused on biomarkers for patients with ER+/HER2- metastatic breast cancer.
EP. 7: Future Outlook and Clinical Pearls for Treating Metastatic Breast Cancer
Rebecca A. Shatsky, MD, looks to the future of biomarker testing in metastatic breast cancer and offers advice to community oncologists.
2 Clarke Drive Cranbury, NJ 08512